ÜBER DIESE EPISODE

Featuring perspectives from Dr Catherine C Coombs, including the following topics:

Early versus delayed addition of obinutuzumab to acalabrutinib and venetoclax in treatment-naïve chronic lymphocytic leukemia (CLL) (0:00)
Feasibility of discontinuation of Bruton tyrosine kinase (BTK) inhibitor therapy in CLL; minimal residual disease and disease monitoring (4:10)
Ongoing Phase III trials of BTK inhibitor/B-cell lymphoma 2 inhibitor combinations in previously untreated CLL (10:05)
Pirtobrutinib as first-line therapy for CLL and long-term safety data (15:22)

CME information and select publications

Wissenschaft

Medizin

Englisch

Vereinigte Staaten

Verwenden SieAPI, um diese Episode inJSONabzurufen

NOTIZEN ANZEIGEN 🔗

00:00:00Early versus delayed addition of obinutuzumab to acalabrutinib and venetoclax in treatment-naïve chronic lymphocytic leukemia (CLL)

00:04:10Feasibility of discontinuation of Bruton tyrosine kinase (BTK) inhibitor therapy in CLL; minimal residual disease and disease monitoring

00:10:05Ongoing Phase III trials of BTK inhibitor/B-cell lymphoma 2 inhibitor combinations in previously untreated CLL

00:15:22Pirtobrutinib as first-line therapy for CLL and long-term safety data

TRANSKRIPT 🔗

Are you the producer of this podcast? Add a podcast transcript

Need Audio-to-Text? Transcribe with Listen411 in Just 60 Seconds

VERGANGENE FOLGEN SUCHEN

Vorhandene Folgen von Hematologic Oncology Update durchsuchen.

Betten Sie diese Suchleiste in Ihre Website ein

WEITERE EPISODEN IN DIESEM PODCAST

Diffuse Large B-Cell Lymphoma — An Interview with Dr L Elizabeth Budde on Employing CD20 x CD3 Bispecific Antibodies

5. Oktober 2026

Featuring an interview with Dr L Elizabeth Budde, including the following topics: Considerations for selecting between bispecific antibodies (BsAbs); monotherapy versus combination therapy (0:00) Management of BsAb-induced cytokine release syndrome and other toxicities (7:35) Use of BsAbs in the f…

00:47:06

SPEICHERN

Clip

$Relapsed/Refractory Multiple Myeloma — Proceedings from a Session Held During the Society of Hematologic Oncology 2026 Annual Meeting$

Relapsed/Refractory Multiple Myeloma — Proceedings from a Session Held During the Society of Hematologic Oncology 2026 Annual Meeting

12. Oktober 2026

Featuring perspectives from Dr Meletios-Athanasios (Thanos) C Dimopoulos, Dr Robert Z Orlowski and Dr Noopur Raje, moderated by Dr Orlowski, including the following topics: Introduction (0:00) New and Emerging Strategies with Bispecific Antibodies in Multiple Myeloma (MM) — Dr Raje (2:20) Utility …

00:59:31

SPEICHERN

Clip

Diffuse Large B-Cell Lymphoma — Proceedings from a Symposium Held in Conjunction with the American Oncology Network

1. Oktober 2026

Featuring perspectives from Dr Ann LaCasce and Dr Stephen "Fred" Divers, moderated by Dr Divers, including the following topics: Introduction (0:00) First-Line Treatment (1:33) Bispecific Antibodies and Chimeric Antigen Receptor T-Cell Therapy (20:36) CME information and select publications

00:50:22

SPEICHERN

Clip

Chronic Lymphocytic Leukemia — Investigators Discuss Optimal Management

8. Oktober 2026

Featuring perspectives from Dr Catherine C Coombs and Dr Matthew S Davids, including the following topics: Introduction (0:00) Minimal Residual Disease Assays in Community-Based Practice (1:24) New Developments in Previously Untreated Chronic Lymphocytic Leukemia (CLL) — Dr Davids (8:12) Richter T…

00:58:15

SPEICHERN

Clip

Rechtliche Hinweise: Der auf dieser Seite eingebettete Podcast und das Bildmaterial stammen von Dr. Neil Love, das Eigentum seines Eigentümers ist und nicht mit Listen Notes, Inc. verbunden ist oder von diesen unterstützt wird.